Atai Life Sciences N.V.
ATAI
$4.83
$0.091.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 163.37% | -- | -127.78% | -54.02% | 58.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 163.37% | -- | -127.78% | -54.02% | 58.72% |
| Cost of Revenue | -- | -3.49% | -- | -- | -- |
| Gross Profit | 163.37% | 17.34% | -127.78% | -54.02% | 58.72% |
| SG&A Expenses | 11.22% | -8.84% | -42.27% | -24.69% | -19.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.04% | -6.13% | -12.62% | -15.89% | -18.83% |
| Operating Income | 1.77% | 13.14% | 12.56% | 15.77% | 19.25% |
| Income Before Tax | 52.05% | 4.53% | -87.67% | -160.74% | -71.89% |
| Income Tax Expenses | 117.96% | 161.24% | 64.40% | -174.79% | -295.68% |
| Earnings from Continuing Operations | 51.64% | 3.33% | -103.69% | -160.66% | -69.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -70.18% | -94.89% | -96.12% | -97.14% | -92.18% |
| Net Income | 51.62% | 1.06% | -112.98% | -159.41% | -73.45% |
| EBIT | 1.77% | 13.14% | 12.56% | 15.77% | 19.25% |
| EBITDA | 2.34% | 13.79% | 12.97% | 15.85% | 19.31% |
| EPS Basic | 60.51% | 10.83% | -110.42% | -157.64% | -68.46% |
| Normalized Basic EPS | 57.35% | 11.04% | 9.05% | -8.79% | -72.64% |
| EPS Diluted | 60.51% | 10.83% | -109.15% | -165.48% | -68.46% |
| Normalized Diluted EPS | 57.35% | 11.04% | 9.05% | -24.01% | -72.64% |
| Average Basic Shares Outstanding | 22.56% | 10.94% | 1.18% | 3.10% | 2.95% |
| Average Diluted Shares Outstanding | 22.56% | 10.94% | 1.18% | -9.54% | 2.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |